Acute Treatment With Fingolimod Does Not Confer Long-Term Benefit in a Mouse Model of Intracerebral Haemorrhage
Intracerebral haemorrhage (ICH) has no specific treatment, but accounts for up to 15% of all strokes and has the highest mortality. Fingolimod (FTY720) is an immunomodulator approved for the management of multiple sclerosis, with abundant evidence of efficacy in experimental ischemic stroke, and mor...
Saved in:
Main Authors: | Andrea C. Diaz Diaz (Author), Jennifer A. Shearer (Author), Kyle Malone (Author), Christian Waeber (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities
by: Andrea C. Diaz Diaz, et al.
Published: (2022) -
Immunomodulatory Therapeutic Strategies in Stroke
by: Kyle Malone, et al.
Published: (2019) -
Intracerebral haemorrhage: A rare presentation of phaeochromocytoma
by: Swati Chhikara, et al.
Published: (2021) -
Outcome after Intracerebral Haemorrhage and Decompressive Craniectomy in Older Adults
by: Thomas Kapapa, et al.
Published: (2024) -
Selectivity and specificity of sphingosine-1-phosphate receptor ligands: caveats and critical thinking in characterizing receptor-mediated effects
by: Christian eWaeber, et al.
Published: (2011)